Treatment Outcomes of Patients with BRAF-mutated Metastatic Colorectal Cancer: a Polish Retrospective Cohort Study

Overview

Journal Contemp Oncol (Pozn)

Publisher Termedia

Specialty Oncology

Date 2025 Feb 12

PMID 39935752

Authors

Jolanta Zok

Michal Bienkowski

Barbara Radecka

Agata Kuchar

Szymon Borowiec

Joanna Streb

Michal Jurczyk

Anna Jakiela-Drag

Marek Gelej

Patryk Zajac

Malgorzata Ploch-Glapinska

Renata Duchnowska

Affiliations

Soon will be listed here.

Abstract

Introduction: The BRAF mutation is found in 6-11% of metastatic colo-rectal cancer (mCRC) patients. According to international guidelines for BRAF-mutated mCRC, the triplet chemotherapy FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan) or double chemotherapy with or without bevacizumab, and encorafenib plus cetuximab should be considered in the first- and second-line settings. We aimed to evaluate clinical practices in BRAF-mutated mCRC patients treated at five Polish oncology centers.

Material And Methods: We retrospectively analyzed the data of BRAF- mutated mCRC patients treated between 2011 and 2023. Before starting the first-line treatment, all patients were tested for BRAF and RAS mutations.

Results: One hundred twenty-six patients (median age: 68 years; 55% female, 45% male) from five oncology centers were included. The majority of patients (69, 55%) had a right-sided primary tumor. The first line of chemotherapy was received by 100 patients (79.4%). The majority received doublet chemotherapy: FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin), FOLFIRI (folinic acid, 5-fluorouracil, irinotecan), XELOX (capecitabine, oxaliplatin), and FOLFIRI with bevacizumab: 30 (30%), 47 (47%), 5 (5%), and 3 (3%). Only three patients received FOLFOXIRI; one patient received bevacizumab. The median duration of first-line treatment was 5.26 months (95% CI: 0.03-18.9). Subsequently, 40%, 16%, 5%, and 1% of patients received second, third, fourth, and fifth-line therapy, retrospectively. During the median follow-up of 38.5 months, 96 (79.3%) patients died. The median overall survival from the time of mCRC diagnosis was 13.7 months (95% CI: 11.3-17.6).

Conclusions: This study highlights the unmet need for effective treatment strategies for patients with BRAF-mutated mCRC in Poland.

References

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo.... J Clin Oncol. 2007; 25(13):1670-6. DOI: 10.1200/JCO.2006.09.0928. View

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. View

Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini M . FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol. 2016; 27(5):843-9. DOI: 10.1093/annonc/mdw052. View

Corcoran R, Andre T, Atreya C, Schellens J, Yoshino T, Bendell J . Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer. Cancer Discov. 2018; 8(4):428-443. PMC: 5882509. DOI: 10.1158/2159-8290.CD-17-1226. View

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S . FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16(13):1306-15. DOI: 10.1016/S1470-2045(15)00122-9. View

Keikes L, Kos M, Verbeek X, van Vegchel T, Nagtegaal I, Lahaye M . Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity. Int J Qual Health Care. 2021; 33(2). PMC: 8023581. DOI: 10.1093/intqhc/mzab051. View

Grothey A, Fakih M, Tabernero J . Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol. 2021; 32(8):959-967. DOI: 10.1016/j.annonc.2021.03.206. View

Zarkavelis G, Amylidi A, Torounidou N, Yerolatsite M, Keravasili A, Keramisanou V . Exploring RAS mutation incidence and temporal heterogeneity in metastatic colorectal cancer patients - a single-institution experience utilising circulating tumour DNA. Contemp Oncol (Pozn). 2024; 28(1):45-50. PMC: 11117156. DOI: 10.5114/wo.2024.138899. View

Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A . Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br J Cancer. 2019; 121(6):434-442. PMC: 6738120. DOI: 10.1038/s41416-019-0526-2. View

10.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008; 26(35):5705-12. DOI: 10.1200/JCO.2008.18.0786. View

11.

Diaz Jr L, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022; 23(5):659-670. PMC: 9533375. DOI: 10.1016/S1470-2045(22)00197-8. View

12.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

13.

Seligmann J, Fisher D, Smith C, Richman S, Elliott F, Brown S . Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol. 2016; 28(3):562-568. DOI: 10.1093/annonc/mdw645. View

14.

Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C . Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015; 51(5):587-94. DOI: 10.1016/j.ejca.2015.01.054. View

15.

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T . Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. N Engl J Med. 2019; 381(17):1632-1643. DOI: 10.1056/NEJMoa1908075. View

16.

Liu N, Zhou Y, Lee J . IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021; 21(1):111. PMC: 8168323. DOI: 10.1186/s12874-021-01308-8. View

17.

Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan T . BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. J Natl Cancer Inst. 2021; 113(10):1386-1395. PMC: 7617278. DOI: 10.1093/jnci/djab042. View

18.

Roth A, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D . Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2009; 28(3):466-74. DOI: 10.1200/JCO.2009.23.3452. View

19.

Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J . Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(1):10-32. DOI: 10.1016/j.annonc.2022.10.003. View

20.

Keikes L, Koopman M, Stuiver M, Lemmens V, van Oijen M, Punt C . Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. Acta Oncol. 2020; 59(4):395-403. DOI: 10.1080/0284186X.2020.1722320. View